Drug Profile
Influenza A virus H7N9 vaccine - Seqirus
Alternative Names: 2017 H7N9 IIV - Seqirus; A/H7N9 - Seqirus; Inactivated influenza A/H7N9 virus vaccine - SeqirusLatest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator Seqirus
- Developer National Institute of Allergy and Infectious Diseases; Seqirus
- Class Influenza A virus H7N9 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza A virus H7N9 subtype
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Influenza-A virus H7N9 subtype(Prevention) in USA (IM)
- 26 Sep 2018 National Institute of Allergy and Infectious Diseases plans a phase II trial for Influenza-A virus H7N9 subtype (In volunteers, Prevention) in USA in October 2018 (NCT03682120)
- 01 Apr 2018 Preclinical trials in Influenza-A virus H7N9 subtype (Prevention) in USA (IM)